IPO registrations (S-1, F-1) · Registrants
RedHill Biopharma Ltd.
- SEC CIK
- 1553846 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2024-02-09, last 2026-01-22; 3 initial registrations, 1 amendment
- Outcome
- Declared effective 2024-02-15
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- L3
- Business address
- 21 HA'ARBA'A STREET, Tel Aviv, L3 64739
- Ticker
- RDHL (Nasdaq)
- EDGAR entity type
- other
- Insiders and CEO pay
- RedHill Biopharma Ltd. on the corporate pages
Offering terms
- Shares offered
- 6,465,559
- Listing
- Nasdaq under the symbol RDHL
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: RedHill Biopharma Ltd. EXACT (CIK (EXACT))
- SEC filer: RedHill Biopharma Ltd. EXACT (CIK (EXACT))
Filings 13
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2024-02-09 | F-1 | F-1 (foreign registration) | RedHill Biopharma Ltd. | 0001178913-24-000425 ↗ |
| 2024-02-15 | EFFECT | EFFECT (declared effective) | RedHill Biopharma Ltd. | 9999999995-24-000485 ↗ |
| 2024-04-22 | EFFECT | EFFECT (declared effective) | RedHill Biopharma Ltd. | 9999999995-24-001066 ↗ |
| 2024-08-19 | EFFECT | EFFECT (declared effective) | RedHill Biopharma Ltd. | 9999999995-24-002577 ↗ |
| 2025-06-25 | F-1 | F-1 (foreign registration) | RedHill Biopharma Ltd. | 0001178913-25-002235 ↗ |
| 2025-07-02 | EFFECT | EFFECT (declared effective) | RedHill Biopharma Ltd. | 9999999995-25-002151 ↗ |
| 2025-09-09 | EFFECT | EFFECT (declared effective) | RedHill Biopharma Ltd. | 9999999995-25-002885 ↗ |
| 2025-09-09 | EFFECT | EFFECT (declared effective) | RedHill Biopharma Ltd. | 9999999995-25-002890 ↗ |
| 2025-12-31 | F-1 | F-1 (foreign registration) | RedHill Biopharma Ltd. | 0001178913-25-004158 ↗ |
| 2026-01-22 | F-1/A | F-1/A (amendment) | RedHill Biopharma Ltd. | 0001178913-26-000204 ↗ |
| 2026-01-27 | EFFECT | EFFECT (declared effective) | RedHill Biopharma Ltd. | 9999999995-26-000316 ↗ |
| 2026-05-05 | EFFECT | EFFECT (declared effective) | RedHill Biopharma Ltd. | 9999999995-26-001495 ↗ |
| 2026-07-13 | EFFECT | EFFECT (declared effective) | RedHill Biopharma Ltd. | 9999999995-26-002275 ↗ |
Prospectus pages read 1
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-22 | F-1/A | registration statement | $1.02 | 6,465,559 | $6,617,499 | Nasdaq RDHL | 0 | primary document; price sentence, shares headline, proceeds computed | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Ben-Asher Dror | Director,Officer | Chief Executive Officer | 1 | 2026 | |
| Cabilly Shmuel | Director | 1 | 2026 | ||
| Frish Adi | Officer | Chief Corp & BD Officer | 1 | 2026 | |
| Goldberg Guy Joel | Officer | Chief Business Officer | 1 | 2026 | |
| Ingber Razi | Officer | Chief Financial Officer | 1 | 2026 | |
| Mamluk Roni | Director | 1 | 2026 | ||
| Raday Gilead | Officer | Chief Operating Officer | 3 | 2026 | |
| Reed Kenneth | Director | 1 | 2026 | ||
| Scruggs Rick D | Director,Officer | Chief Commercial Officer | 1 | 2026 | |
| Tsimchi Ofer | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-02-05 | RedHill Biopharma Ltd. | Pharmaceuticals | $10,000,000 | $10,000,000 | 5 | 1 |
| 2023-10-12 | RedHill Biopharma Ltd. | Pharmaceuticals | $4,043,808 | $4,043,808 | 3 | 1 |
| 2023-08-07 | RedHill Biopharma Ltd. | Pharmaceuticals | $2,700,000 | $2,700,000 | 1 | 1 |
| 2021-11-22 | RedHill Biopharma Ltd. | Pharmaceuticals | $10,000,000 | $5,000,000 | 1 | 1 |
| 2019-11-06 | RedHill Biopharma Ltd. | Pharmaceuticals | $48,300,000 | $48,300,000 | 2 | 1 |
| 2014-01-15 | RedHill Biopharma Ltd. | Pharmaceuticals | $2,500,020 | $2,500,020 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | RedHill Biopharma Ltd. | Form D private offerings | CIK (EXACT) | |
| SEC filer | RedHill Biopharma Ltd. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, L3 first:
- CANNAPOWDER, INC. L3
- Rosetta Genomics Ltd. L3
- BIOCANCELL THERAPEUTICS INC. L3
- Can-Fite BioPharma Ltd. L3
- KAMADA LTD L3
- MAPI - PHARMA LTD L3
- NeuroDerm Ltd. L3
- Advanced Inhalation Therapies (AIT) Ltd. L3
- Silenseed Ltd. L3
- SciSparc Ltd. L3
In other datasets, the same topic (Health) in L3:
- Form D issuer: Agada Medical Ltd. (Form D private offerings)
Interests: Pharmaceutical Preparations · Health